Alexion Pharmaceuticals (United States)

Alexion Pharmaceuticals, now part of AstraZeneca, is a global biopharmaceutical company focused on rare diseases. Known for Soliris (eculizumab) and Ultomiris (ravulizumab), complement inhibitor therapies for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. Alexion pioneered complement biology research and develops life-transforming treatments for patients with devastating rare disorders.